Moebius Medical Ltd. news

• Global Phase IIb study to enrol approximately 312 patients, each of whom will receive one of three doses of MM-II or placebo
• Primary endpoint is a reduction in pain from baseline as measured by WOMAC A pain scale at 12 weeks

Israel-based Moebius Medical today announced that the first patient has been dosed in its Phase IIb clinical trial of MM-II, a novel candidate for the treatment of pain in knee osteoarthritis (OA).

The Phase IIb c

• Treatment leverages proprietary liposomes and first-in-class mechanism-of-action to achieve significant, sustainable pain relief
• Phase IIb study expected to begin enrolling by year-end with initial top-line data anticipated in mid-2022

Israel-based Moebius Medical today announced that the US Food and Drug administration (FDA) has cleared their Invest

• Clinical data showed superior efficacy & similar safety of MM-II vs. standard of care (hyaluronic acid) for treatment of pain in osteoarthritis
• Sun Pharma to fund further development of MM-II including completion of Phase 2 and Phase 3 clinical programs and any required preclinical work necessary for regulatory approval
• Sun Pharma has worldwide commercialization & manufacturing rights

Sun Pharma